In yesterday’s Wall Street session, Grifols SA ADR (NASDAQ:GRFS) shares traded at $9.66, up 1.15% from the previous session.
As of this writing, 5 analysts cover Grifols SA ADR (NASDAQ:GRFS). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $19.50 and a low of $10.00, we find $17.62. Given the previous closing price of $9.55, this indicates a potential upside of 84.5 percent. GRFS stock price is now 8.42% away from the 50-day moving average and 9.36% away from the 200-day moving average. The market capitalization of the company currently stands at $2.48B.
There are 2 analysts who have given it a hold rating, whereas 2 have given it a buy rating. Brokers who have rated the stock have averaged $15.71 as their price target over the next twelve months.
A total of 0.06% of the company’s stock is owned by insiders.
Wednesday morning saw Grifols SA ADR (NASDAQ: GRFS) opened at $9.58. During the past 12 months, Grifols SA ADR has had a low of $6.50 and a high of $10.97. As of last week, the company has a debt-to-equity ratio of 1.71, a current ratio of 2.56, and a quick ratio of 0.79. According to the stock market information, the enterprise value for the company is $19.80B, which is based on a 1380.00 price-to-earnings ratio, a 40.71 price-to-earnings-growth ratio, and a beta of 0.55. The fifty day moving average price for GRFS is $8.91 and a two-hundred day moving average price translates $8.83 for the stock.
The latest earnings results from Grifols SA ADR (NASDAQ: GRFS) was released for Sep, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $0.12, missing analysts’ expectations of $0.24 by -0.12. This compares to $0.27 EPS in the same period last year. The net profit margin was 0.07% and return on equity was 0.07% for GRFS. The company reported revenue of $1.81 billion for the quarter, compared to $1.43 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 26.99 percent. For the current quarter, analysts expect GRFS to generate $1.88B in revenue.
Grifols SA ADR(GRFS) Company Profile
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada and internationally. The Biopharma segment provides plasma derivatives products, including Gamunex/Gamunex-C Immune Globulin Injection, Flebogamma Immune Globulin Intravenous, Xembify Immune Globulin Subcutaneous solution, HyperRAB Rabies Immune Globulin, Prolastin/Prolastin-C/Prolastin-C Liquid/Prolasplan/Prolastina/Pulmolast/Lynspad Alpha 1-Proteinase Inhibitor, Fanhdi and Alphanate, Antihemophilic Factor/von Willebrand factor Complex, Koate-DVI Antihemophilic Factor, Albutein/Albutein Flexbag/ Human Albumin Grifols/Plasbumin Albumin, and Vistaseal/Veraseal; and Tavlesse, a non-plasma derivative medicinal product. The Diagnostic segment offers transfusion medicine, which includes Procleix Panther systems/Procleix Panther with Automation Ready technology, Automated NAT blood screening systems, assays, software, WADiana/Erytra/Erytra Eflexys analyzers, BLOODchip ID/IDCore/IDHPA/IDRHD/IDCORE/BIDS, and antigens; and clinical and diagnostics products, such as Promonitor and Alpha1D. The Bio Supplies segment provides human biological materials for life sciences research and the development and manufacturing of pharmaceutical and diagnostic products. The Others segment offers healthcare solutions, which provides services and manufactures products, including parenteral solutions, robotics, and software used by hospitals, blood banks, plasma collection centers and other healthcare systems. The company’s products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. Grifols, S.A. has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products, and with GIANT and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1940 and is headquartered in Barcelona, Spain.
